AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

LOE Approaching

moxifloxacin hydrochloride

Bayer
NDAINTRAVENOUSSOLUTION
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
25

Mechanism of Action

12.1 Mechanism of Action Moxifloxacin hydrochloride is a member of the fluoroquinolone class of antibacterial agents [see ] . 12.2 Pharmacodynamics Photosensitivity Potential A study of the skin response to ultraviolet (UVA and UVB) and visible radiation conducted in 32 healthy volunteers (8 per…

Indications (25)

Haemophilus influenzaeMoraxella catarrhalismethicillin-susceptible Staphylococcus aureusKlebsiella pneumoniaeMycoplasma pneumoniaeSkin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureusEscherichia coliBacteroides fragilisStreptococcus anginosusStreptococcus constellatusEnterococcus faecalisProteus mirabilisClostridium perfringensBacteroides thetaiotaomicronincluding pneumonicsepticemic plaguedue to susceptible isolates of Yersinia pestisprophylaxis of plague in adult patientsHaemophilus parainfluenzaedevelopment of drug-resistant bacteriamaintain the effectiveness of moxifloxacin tabletsother antibacterial drugsmoxifloxacin tablets should be used only to treatprevent infectionsstrongly suspected to be caused by susceptible bacteria

Clinical Trials (5)

NCT05413980N/ACompleted

Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery

Started Jan 2024
102 enrolled
Post Operative Endophthalmitis
NCT01049022Phase 1Completed

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Started May 2010
31 enrolled
Infections
NCT01073891Phase 1Completed

Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

Started May 2010
24 enrolled
Healthy
NCT01096511N/ACompleted

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Started Dec 2009
1,001 enrolled
Secondary PeritonitisAbscess, Intra-Abdominal
NCT00879008N/ACompleted

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Started Dec 2009
345 enrolled
Chronic Bronchitis
Company
Bayer
Bayer
LEVERKUSEN, Germany
4 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers